Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

27 Jan 2021

Abstract excerpt

Importance: Ruxolitinib, a selective inhibitor of the Janus kinases 1/2 signaling pathway, has shown a significant response in steroid-refractory chronic graft-vs-host disease (SR-cGVHD), a major cause of morbidity and mortality in individuals who have undergone allogeneic hematopoietic stem cell transplantation (HSCT). Objectives: To investigate the clinical response to ruxolitinib in patients with SR-cGVHD...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Hematopoietic Stem Cell Transplantation
Share to Platelet Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33502484
DOI: 10.1001/jamanetworkopen.2020.34750

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell TransplantationPMID 33502484Read ↗

Emerging novel therapies for steroid-refractory acute graft-versus-host disease: recent advances and future directionsSemantic proximity Read ↗

Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host DiseaseSemantic proximity Read ↗

New molecules in the therapy of chronic graft-versus-host diseaseSemantic proximity Read ↗

Graft-versus-host diseaseSemantic proximity Read ↗

Chronic graft-versus-host diseaseSemantic proximity Read ↗

Evaluating Axatilimab as a treatment option for chronic graft-versus-host diseaseSemantic proximity Read ↗

Acute and chronic Graft-versus-host disease after hematopoietic stem cell transplantationSemantic proximity Read ↗

Role of ROCK2 inhibitors in the treatment of chronic graft-versus-host diseaseSemantic proximity Read ↗

Current Challenges in Chronic Graft-versus-Host DiseaseSemantic proximity Read ↗

Chronic Graft-vs-Host DiseaseSemantic proximity Read ↗

Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.Semantic proximity Read ↗

Targeting Immune Signaling Pathways in Graft-Versus-Host Disease; A Signaling-Centric Review of Future Therapeutic StrategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.